Category: Our News

MONTREAL, November 2, 2022 ─ The Canadian Cancer Society (CCS), CQDM, the Cole Foundation and Oncopole – pôle cancer du FRQS announced, today, grants of $8,485,132 to finance four research projects in Quebec, as part of the Pediatric Cancer Research Initiative. This funding, which will take place over three years, is part of a unique partnership…

ABOUT CQDM Since its creation, CQDM has raised nearly $190 million to fund the development of approximately 130 drugs addressing major health challenges, including cancer, neurodegenerative and metabolic diseases. CQDM is a biopharmaceutical research consortium whose mission is to fund the development of innovative tools and technologies that accelerate the development of safe and effective…

ABOUT CQDM Since its creation, CQDM has raised nearly $190 million to fund the development of approximately 130 drugs addressing major health challenges, including cancer, neurodegenerative and metabolic diseases. CQDM is a biopharmaceutical research consortium whose mission is to fund the development of innovative tools and technologies that accelerate the development of safe and effective…

MONTREAL, August 30, 2022 – CQDM is very pleased to announce the nomination of John Delaney and Jennifer Hamilton as members of the Scientific Advisory Board (SAB). The SAB is a key committee for CQDM as it provides strategic guidance regarding biopharmaceutical innovation and oversees the selection of projects funded by CQDM. John Delaney is…

ABOUT CQDM Since its creation, CQDM has raised nearly $190 million to fund the development of approximately 130 drugs addressing major health challenges, including cancer, neurodegenerative and metabolic diseases. CQDM is a biopharmaceutical research consortium whose mission is to fund the development of innovative tools and technologies that accelerate the development of safe and effective drugs. We…

Montreal, Quebec, July 12, 2022 ─ CQDM, the Quebec Breast Cancer Foundation and Theratechnologies today announced close to CAN $2 million of funding for a collaborative research project that aims to demonstrate the efficacy and safety of a potential innovative treatment for patients affected by metastatic cancer. This public-private partnership is made possible through a…

Montreal (Quebec), June 16th, 2022 – CQDM is proud to announce the funding of a project in collaboration with the centre hospitalier universitaire (CHU) de Québec-Université Laval, SPM Therapeutics, and the Fondation du CHU de Québec. The funding, totalling $103,158, was made possible by a grant of $51,847 from the Ministère de l’Économie et de…

Industrial research clusters hail a relevant and ambitious policy Quebec City, May 19, 2022 – The sector-based industrial research clusters (RSRIs), which form critical innovation and technology transfer hubs, welcome the new Quebec Research and Innovation Investment Strategy 2022-2027 (SQRI²) presented today by the Legault government. “This strategy is right on target; one of the…

Montreal, Quebec, May 13, 2022 – CQDM is delighted with the measures announced as part of the updated Quebec Life Sciences Strategy, unveiled yesterday by Minister Fitzgibbon at the Effervescence event. The Strategy has a total budget of $211 million, including $110 million in new funding for the 2022-2025 period. The measures set out in…

ABOUT CQDM  Since its creation, CQDM has raised nearly $190 million to fund the development of approximately 130 drugs addressing major health concerns, including cancer, and neurodegenerative and metabolic diseases. CQDM is a biopharmaceutical research consortium with the socially responsible mission of funding the development of innovative tools and technologies that accelerate the development of safe and…